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Abstract The calcipotriol/betamethasone dipropionate
fixed-combination gel is widely used for topical treatment
of psoriasis vulgaris. It has been hypothesized that calci-
potriol counteracts glucocorticoid-induced skin atrophy
which is associated with changes in the extracellular matrix
(ECM). To elucidate the combined effects of calcipotriol
and betamethasone on key ECM components, a compara-
tive study to the respective mono-treatments was carried
out. The effect on collagen I synthesis, matrix metallo-
proteinase (MMP) secretion, and hyaluronic acid (HA)
production was investigated in primary human fibroblast
and keratinocyte cultures as well as in a human skin
explant model. We show that calcipotriol counteracts
betamethasone-induced suppression of collagen I synthesis.
Similarly, calcipotriol and betamethasone have opposing
effects on MMP expression in both fibroblasts and kerati-
nocytes. Moreover, calcipotriol is able to restore beta-
methasone-impaired HA synthesis in keratinocytes and
prevent betamethasone-induced epidermal thinning in
minipigs upon treatment with the calcipotriol/betametha-
sone gel. In summary, our results show for the first time in
primary human skin cultures that calcipotriol reduces early
signs of betamethasone-induced skin atrophy by modula-
tion of key ECM components. These results indicate that
the calcipotriol component of the fixed-combination gel
counteracts the atrophogenic effects of betamethasone on
the skin.
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Introduction
Topical use of glucocorticoids can lead to the development
of skin atrophy which is characterized by reduced skin
thickness and elasticity, telangiectasia and purpura [3].
Glucocorticoids have been shown to reduce the prolifera-
tion and size of keratinocytes and to impair the skin barrier
through inhibition of lipid synthesis [7, 15, 17]. Gluco-
corticoids also decrease the proliferation of fibroblasts and
the production of extracellular matrix (ECM) proteins [13,
27]. Importantly, glucocorticoids inhibit collagen synthesis
in fibroblasts and reduce the expression and activity of
collagenases and other matrix metalloproteinases (MMPs)
in keratinocytes and fibroblasts [2, 4, 18, 23, 28]. Fur-
thermore, through regulation of hyaluronan synthase
(HAS)-2 in fibroblasts and keratinocytes, glucocorticoids
decrease the level of hyaluronic acid (HA), a glycosami-
noglycan which plays an important role in maintaining
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dermal and epidermal structure, flexibility and water
binding capacity [1, 8, 26, 34]. By affecting important
ECM components, glucocorticoids restrict the dynamic
remodeling of the skin, thus contributing to skin atrophy.
In contrast, studies mostly performed in mice suggest
that vitamin D receptor (VDR) agonists have opposing
effects on many of the cellular and molecular mechanisms
underlying glucocorticoid-induced skin atrophy, including
effects on cell proliferation, epidermal lipids and antimi-
crobial peptides [9–11, 14]. Combination of betamethasone
with calcipotriol has proven to be an effective topical
treatment of psoriasis vulgaris that can be used for up to a
year with very low incidence of skin atrophy [19]. These
observations suggest that combination with a VDR agonist
has the potential to mitigate the unwanted cutaneous side
effects associated with topical glucocorticoid mono-ther-
apy [29]. The present study is the first to investigate the
combined effects of vitamin D agonists and glucocorticoids
on key ECM components at the cellular and molecular
level in primary human skin cultures.
Materials and methods
Test reagents
Mono-components of the fixed-combination gel (Daivobet/
Dovobet) containing betamethasone dipropionate
(0.5 mg/g) and calcipotriol (50 lg/g) were produced in the
corresponding gel vehicle at LEO Pharma. Stock solutions
of calcipotriol (MC 00903; LEO Pharma) and betametha-
sone dipropionate (provided by LEO Pharma) with a con-
centration of 10 mM were prepared in DMSO. The stock
solutions were diluted in cell culture medium at the time of
use.
Cell cultures
Cultures of primary human dermal fibroblasts (Invitrogen
Life Technologies, Carlsbad, CA, USA) were propagated
in M106 medium supplemented with Low Serum Growth
Supplement consisting of 1.9 % fetal bovine serum (FBS),
1 lg/mL hydrocortisone, 10 ng/mL human epidermal
growth factor (EGF), 3 ng/mL basic fibroblast growth
factor (bFGF), 10 lg/mL heparin. Furthermore, gentamy-
cin was added to the culture medium. Cells were incubated
in a humidified atmosphere of 5 % CO2 at 37 C. The
medium was changed the day before and on the day of
treatment (90 % confluent cultures) to M106 medium
containing 1.9 % charcoal-treated FBS and hydrocortisone
was omitted from the supplement to appropriately assess
the effect of betamethasone dipropionate. Supplementation
with the other factors mentioned above is needed to
maintain proliferative cultures with normal fibroblast
morphology.
Cultures of primary human epidermal keratinocytes
(Invitrogen Life Technologies, Carlsbad, CA, USA) were
grown in EpiLife medium supplemented with 0.2 ng/mL
human EGF, 0.2 % bovine pituitary extract (BPE), 5 lg/
mL bovine insulin, 5 lg/mL bovine transferrin, 0.18 lg/
mL hydrocortisone and gentamycin. Cells were incubated
in a humidified atmosphere of 5 % CO2 at 37 C. The
medium was changed the day before and on the day of
treatment (80 % confluent cultures) to EpiLife medium
without any supplement and containing 1.2 mM calcium to
induce differentiation. Keratinocytes can be maintained in
non-supplemented medium for a few days without loss of
viability.
Cell cultures were treated with the compounds in
duplicate for the indicated time points. The final concen-
tration of the compounds was 100 nM for calcipotriol and
1 lM for betamethasone both for single treatments and for
the combination. These concentrations are based on
exposure in ex vivo pig and human skin after topical
application of the calcipotriol/betamethasone fixed-com-
bination product. Supernatants from fibroblast and kerati-
nocyte cultures were collected for analysis of secreted
proteins. Four independent experiments were performed
using fibroblasts from two different donors. In three of the
experiments, fibroblast cultures were processed for RNA
purification and qPCR analysis. Five independent experi-
ments using keratinocytes from three different donors were
performed.
Quantitative real-time PCR
Total RNA was extracted from cells using the RNeasy mini
kit (Qiagen, Germantown, MD, USA) according to the
instructions provided. cDNA synthesis was performed with
the High-Capacity cDNA Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). 2.5 lL of
cDNA (equivalent to 5 ng RNA) from each sample was
amplified in a total volume of 10 lL by quantitative real-
time PCR using Taqman Gene Expression Assays
(COL1A1-Hs00164004_m1, HAS2-Hs00193435_m1,
GAPDH-Hs99999905_m1) and PRISM7900HT sequence
detection system (SDS 2.3) from Applied Biosystems.
GAPDH was used for normalization as it was found to be a
stable reference gene not affected by calcipotriol or beta-
methasone treatment in human dermal fibroblasts.
Immunoassays
Analysis of secreted CICP (C-terminal pro-peptide of type
I collagen) in cell culture supernatants from fibroblasts was
performed using a human CICP EIA kit (Quidel, San
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Diego, CA, USA). Detection of MMP-1 and MMP-3 in cell
culture supernatants from fibroblasts and keratinocytes was
carried out by the use of a human MMP 3-plex ultra-sen-
sitive kit and measured on a MSD platform (Meso Scale
Discovery, Gaithersburg, MD, USA). Hyaluronic acid
(HA) was measured in the cell culture supernatants from
fibroblasts and keratinocytes by a human HA competitive
ELISA kit (Echelon Biosciences, Salt Lake City, UT,
USA).
Production and culture of NativeSkin models
Genoskin collected anonymized human skin samples from
donors that underwent abdominoplasty procedure and had
given their written informed consent. Donors did not have
any dermatological disorders and did not use glucocorti-
coid treatment. Full ethical approval for the study protocol
was obtained from the French ethical research committee
(Comite´ de Protection des Personnes) and authorization
was given from the French ministry of Research. All
studies were conducted according to the Declaration of
Helsinki protocols.
Immediately following surgery, skin samples were
transported at 4 C before being processed to produce
NativeSkin models. Subcutaneous adipose tissue was
removed from the skin sample. 8 mm punch biopsies were
excised and embedded in a proprietary fibrin-based matrix
in transwells (Filter pore size 1 lm, Millicell). The epi-
dermal surface of skin biopsies was left in contact with the
air and the dermal compartment was immersed in the
matrix. NativeSkin models were cultured in 12-well
plates in a proprietary and chemically-defined hydrocorti-
sone- and serum-free medium supplemented with 100 lg/
mL penicillin and 100 lg/mL streptomycin in a humidified
atmosphere of 5 % CO2 at 37 C. The medium was
changed every day. 10 lL of formulation was applied on
the epidermal surface using a positive displacement pipette
once daily for 6 days. Before each re-application of for-
mulation, any remaining formulation was removed with a
cotton swab.
Histological and immunofluorescence analyses
Treated NativeSkin models were fixed in 10 % neutral-
buffered formalin and embedded in paraffin wax. 5 lm
cross-sections were stained with hematoxylin–eosin or
anti-pro-COLA1 (MAB1912, Merck Millipore, Billerica,
MA, USA), anti-MMP-1 (EP1237Y, ab52631, Abcam,
Cambridge, UK), anti-MMP-3 (ab53015, Abcam) and anti-
HAS-2 (ab140671, Abcam) antibodies. Skin sections were
stored at 60 C for 1 h prior to incubation with antibodies
for 1 h. A specific signal was detected using secondary
antibodies conjugated to Alexa Fluor 555 dye (Invitrogen
Life Technologies, Carlsbad, CA, USA). DAPI (D9542,
Sigma-Aldrich, St. Louis, MO, USA) was used to coun-
terstain skin sections for the immunofluorescence analyses.
Images were obtained with a Nikon Eclipse 80i fluores-
cence microscope and its dedicated NIS-Element AR
software. We made sure that pixel intensity was not satu-
rated by turning on the pixel saturation indication button,
provided in the NIS-Element AR software. All images for a
respective ECM marker were obtained with strictly the
same parameters such as signal intensity and duration of
exposure. Signals were quantified by analyzing images
with the ImageJ software and expressed in arbitrary units
of fluorescence corresponding to the sum of the gray values
of all the pixels in the selection divided by the number of
pixels. Results are normalized relative to vehicle controls.
Minipig study
Eight five-month-old female Go¨ttingen minipigs (9–11 kg
bodyweight) were purchased from Ellegaard Go¨ttingen
minipigs, Denmark. Animals were group-housed with
unlimited access to food and water and acclimatized for
2 weeks before start of study. Animals were anaesthetized
with a mixture of zoletil, xylazine, ketamine and butor-
phanol i.v. Ten test fields of 6.25 cm2 each (on the back
and behind the ears) were delineated with tattoo. A 5-mm
punch biopsy was taken from the upper left corner of each
test field and the wound was closed with a metal clip.
80 lL of the designated formulation was applied topically
to the test field Monday to Friday for a total period of
4 weeks. The animals were observed daily and any sign of
local skin reaction was noted. Treatment of the test fields
occurred in a randomized manner. At the end of the study
all animals were euthanized by an overdose of pentobar-
bital i.v. and full-thickness test areas were excised. All
animal procedures were conducted in accordance with
institutional guidelines and licensed by the Danish Animal
Experiments Inspectorate. A 5-mm punch biopsy was
obtained from each area and fixed in 4 % formaldehyde,
embedded in paraffin, sectioned at 5 lm and stained with
Masson’s trichrome. Slides were analyzed using Visi-
omorphTM system version 4.3.2.0 (Visiopharm, Hørsholm,
Denmark). The mean epidermal thickness (MET) was
determined by dividing the total epidermal area with the
epidermal surface length.
Statistical analysis
For in vitro studies, statistical comparison between groups
was performed by one-way ANOVA followed by Tukey’s
multiple comparison test using GraphPad Prism v. 5.0
(GraphPad, San Diego, CA, USA). For the minipig study, a
mixed effects model was fitted to the epidermal thickness
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measurements, with thickness as a fixed effect and animal
and treatment field as random effects. The vehicle group
was used as reference for testing significance of treatment
using R version 2.15.2.
Results
Calcipotriol counteracts betamethasone-induced
suppression of ECM components in primary human
fibroblasts and keratinocytes in vitro
To investigate the effects of betamethasone and calcipotriol
on ECM components, cultures of primary human dermal
fibroblasts, and differentiated primary human epidermal
keratinocytes were treated with calcipotriol (100 nM), beta-
methasone (1 lM), calcipotriol in combination with beta-
methasone (100 nM/1 lM; ratio 1:10 as in the fixed-
combination product) or a corresponding vehicle control
(0.1 % DMSO). Final concentrations of calcipotriol and
betamethasone used in this study are based on exposure in
ex vivo pig and human skin after topical application of the
calcipotriol/betamethasone fixed-combination product. No
compound-induced changes in cell morphology or confluence
were observed in comparison with the vehicle control. The
extracellular protein collagen I, matrix metalloproteinases
MMP-1 and MMP-3, and the glycosaminoglycan hyaluronic
acid were chosen as representative ECM components to be
analyzed in this study. Gene expression and protein analysis
using cells from different donors were performed to address
the treatment effect on ECM components. Overall comparable
treatment effects were found at 24 and 48 h and across dif-
ferent donors as presented in Supplementary Figs. 1 and 2.
Representative experiments are shown in Figs. 1, 2 and 3.
For collagen I, which is synthesized by fibroblasts as
pro-collagen and processed to mature collagen (tropo-col-
lagen) by cleavage of N- and C-terminal pro-peptides,
COL1A1 mRNA and secretion of the C-terminal pro-pep-
tide CICP were chosen as readouts. In the fibroblast cul-
tures, COL1A1 mRNA expression was slightly decreased
by betamethasone but moderately increased by calcipotriol
with a statistically significant difference between the two
mono-treatments (Fig. 1a). COL1A1 mRNA expression
was comparable in fibroblasts treated with either calcipot-
riol alone or the calcipotriol/betamethasone combination.
Furthermore, the compiled data from several independent
experiments showed a significant difference between
betamethasone and the combination treatment (Supple-
mentary Fig. 1a). Calcipotriol and betamethasone also
showed opposing effects on CICP as secreted levels were
significantly reduced by treatment with betamethasone but
remained unaffected by calcipotriol (Fig. 1b). Again,
combination of calcipotriol with betamethasone resulted in
levels of CICP that were comparable to the vehicle control
and significantly higher than those observed for beta-
methasone mono-treatment.
Matrix metalloproteinases are ECM-degrading enzymes
produced by fibroblasts and keratinocytes that are of crit-
ical importance for ECM homeostasis in the skin. Treat-
ment with betamethasone alone resulted in a reduced
secretion of both MMP-1 and -3 in fibroblast as well as
keratinocyte cultures (Fig. 2a–d). In contrast, secretion of
MMP-3 was markedly increased by calcipotriol in both
fibroblasts and keratinocytes (Fig. 2b, d). Similarly, treat-
ment with calcipotriol significantly increased MMP-1
secretion in keratinocytes (Fig. 2c); however, little to no




































































Fig. 1 Collagen I synthesis is not decreased by combination treat-
ment with betamethasone and calcipotriol. Cultures of human dermal
fibroblasts were treated in duplicates with 100 nM calcipotriol, 1 lM
betamethasone, 100 nM calcipotriol ? 1 lM betamethasone or a
corresponding vehicle control (0.1 % DMSO). a COL1A1 mRNA
expression was analyzed by qPCR after 24 h of treatment and
normalized to GAPDH and b CICP (C-terminal pro-peptide of type I
collagen) was measured by ELISA in culture supernatants after 48 h
of treatment. The values ± SD are representative of three (a) and four
(b) independent experiments using two donors. *P \ 0.05 (one-way
ANOVA test)
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fibroblasts (Fig. 2a; Supplementary Fig. 1c). Again, when
combined with betamethasone, calcipotriol managed to
counteract glucocorticoid-induced suppression of MMP-3
secretion in fibroblasts as well as keratinocytes (Fig. 2b, d).
The counteracting effect of calcipotriol in combination
with betamethasone is further supported by the findings for
MMP-1, showing a partial effect in keratinocytes (Fig. 2c)
which was significantly different from betamethasone
mono-treatment based on analysis of compiled data from
independent experiments (Supplementary Fig. 2a). In
contrast, combination of calcipotriol with betamethasone
did not increase MMP-1 secretion in fibroblasts in line with
the minimal effect of calcipotriol mono-treatment
(Fig. 2a).
The glycosaminoglycan HA is synthesized by three
different hyaluronan synthases (HAS)-1, -2, and -3
expressed in fibroblasts as well as keratinocytes. In the
present study, HA synthesis was monitored by determina-
tion of secreted HA in cell culture supernatants. Addi-
tionally, cellular expression of HAS2 mRNA was analyzed.
In this setting, treatment with betamethasone alone sig-
nificantly reduced HA secretion from fibroblasts as well as
keratinocytes (Fig. 3a, c). In contrast, HA secretion from
fibroblasts remained unaffected by calcipotriol mono-
treatment. In the combination, calcipotriol was not able to
counteract the betamethasone-induced suppression of HA
secretion in fibroblasts in line with the lack of effect by
calcipotriol mono-treatment (Fig. 3a). Analysis of HAS2
mRNA expression in fibroblasts showed a picture similar to
that observed for HA secretion, i.e. comparable levels for
vehicle and calcipotriol treatment and a decrease in HAS2
mRNA expression by betamethasone and the calcipotriol/
betamethasone combination (Fig. 3b). In keratinocytes,
however, calcipotriol alone significantly increased HA
secretion and was able to fully counteract the glucocorti-
coid-induced inhibition of HA secretion when combined
with betamethasone (Fig. 3c).
The counteracting effect of calcipotriol
on betamethasone-induced decrease in ECM proteins
can be translated to a human skin explant model
We next investigated if the findings from in vitro cultures




















































































































































Fig. 2 Calcipotriol and
betamethasone have opposing
effects on MMP expression.
Cultures of human dermal
fibroblasts and human
epidermal keratinocytes (in the
presence of 1.2 mM calcium)
were treated as described in
Fig. 1 and analyzed for levels of
MMP-1 and MMP-3 in culture
supernatants after 48 h of
treatment using a MSD kit.
a MMP-1 and b MMP-3 levels
detected from fibroblast cultures
and c MMP-1 and d MMP-3
levels detected from
keratinocyte cultures. The
values ± SD are representative
of four independent experiments
using two donors (a, b) and five
independent experiments using
three donors (c, d). *P \ 0.05;
**P \ 0.01; ***P \ 0.001
(one-way ANOVA test)
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repeated topical application of the calcipotriol/betametha-
sone gel. For this purpose, we used a recently developed
skin explant model (NativeSkin) which consists of full-
thickness human skin biopsies that are embedded in a
proprietary fibrin-based matrix in transwells and cultured
in hydrocortisone- and serum-free medium (Supplementary
Fig. 3). Histological features of normal skin are maintained
during ex vivo culture of the NativeSkin model for up to
1 week (Supplementary Fig. 4). Furthermore, repeated
daily topical application of the vehicle gel for 6 days did
not affect skin morphology and epidermal layers demon-
strating that the vehicle gel was well tolerated in this skin
model (Supplementary Fig. 5). Therefore, this treatment
regimen was used in the NativeSkin model to investigate
the expression of pro-collagen I, MMP-1, MMP-3, and
HAS-2 by quantitative immunofluorescence analysis fol-
lowing topical application of gel formulations containing
betamethasone dipropionate, calcipotriol and the fixed-
combination of calcipotriol and betamethasone dipropio-
nate, using the corresponding vehicle gel as a control. A
representative example of two independent experiments in
different donors is shown in Fig. 4.
Pro-collagen I immunoreactivity was found in the upper
papillary dermis in conjunction with the stratum basale in
vehicle-treated samples (Fig. 4a). Betamethasone mono-
treatment resulted in a mild reduction of pro-collagen I
expression compared with the vehicle gel (Fig. 4a, b).
Treatment with calcipotriol alone or with the calcipotriol/
betamethasone gel resulted in levels of pro-collagen I
comparable to the vehicle control indicating that calcipot-
riol was able to prevent the betamethasone-induced sup-
pression of pro-collagen I. Thus, the counteracting effect of
calcipotriol on betamethasone-induced suppression of col-
lagen I synthesis found in vitro could be translated to
human skin explants treated with the calcipotriol/beta-
methasone gel.
Immunoreactivity of MMP-1 and MMP-3 was present in
all viable layers of the epidermis and detected in some der-
mal fibroblasts in vehicle-treated samples (Fig. 4a). Beta-
methasone mono-treatment did not affect expression of
MMP-1 whereas expression of MMP-3 was clearly sup-
pressed (Fig. 4a, b). Calcipotriol mono-treatment slightly
enhanced the expression of MMP-1 and resulted in compa-
rable levels of MMP-3 as found in the vehicle control.











































































































bFig. 3 Betamethasone-impaired production of HA is counteracted by
calcipotriol in keratinocytes but not in fibroblasts. Cultures of human
dermal fibroblasts and human epidermal keratinocytes (in the
presence of 1.2 mM calcium) were treated as described in Fig. 1.
HA was measured by ELISA in supernatants from a fibroblast and
c keratinocyte cultures after 48 h of treatment and b HAS2 mRNA
expression was analyzed by qPCR after 24 h of treatment and
normalized to GAPDH. The values ± SD are representative of four
(a) and three (b) independent experiments using two donors and c five
independent experiments using three donors. *P \ 0.05; **P \ 0.01;
***P \ 0.001 (one-way ANOVA test)
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that calcipotriol could still increase epidermal expression of
MMP-1 even in the presence of betamethasone and coun-
teracted the betamethasone-induced decrease of MMP-3. In
line with in vitro results from monolayer cultures, beta-
methasone and calcipotriol showed opposing effects on
MMP expression in the human skin explant model.
HAS-2 immunostaining was detected in all layers of the
epidermis and in some dermal fibroblasts in vehicle-treated
samples (Fig. 4a). The epidermal staining of HAS-2 was
reduced by betamethasone mono-treatment whereas no
difference was detected in the dermis (Fig. 4a, b). Calci-
potriol mono-treatment resulted in slightly elevated levels
of epidermal HAS-2 as compared with the vehicle control.
Treatment with the calcipotriol/betamethasone gel showed
that calcipotriol could restore betamethasone-decreased
HAS-2 expression to levels comparable to the vehicle
control. This is in line with the in vitro data on HA
secretion where calcipotriol was able to counteract beta-
methasone-induced reduction of HA in keratinocytes. At
the investigated time point, none of the treatments induced
epidermal or dermal thinning based on Masson Trichrome-
stained sections (data not shown). This result is consistent
with clinical findings demonstrating skin thinning as a
long-term treatment effect.
Calcipotriol prevents betamethasone-induced epidermal
thinning in minipigs correlating to HA modulation
Levels of HA in the skin may affect keratinocyte prolifera-
tion and epidermal thickness. Therefore, we investigated
whether the differential effects of betamethasone and calci-
potriol on HA observed in keratinocytes would translate into
effects on epidermal thickness in vivo. For this purpose,
minipigs were used to investigate drug-induced effects on
epidermal thickness following topical treatment for a total of
4 weeks with vehicle gel, the calcipotriol/betamethasone
gel, or the mono-components in the corresponding vehicle
gel. Upon termination, mean epidermal thickness was ana-
lyzed on Masson’s trichrome-stained sections and found to
be similar in the untreated and vehicle-treated group (Fig. 5).
Fig. 4 Calcipotriol counteracts betamethasone-induced decrease in
ECM proteins upon topical application of the fixed-combination gel
in a human skin explant model. a Immunostaining of skin cross-
sections with anti-pro-COL1A1, anti-MMP-1, anti-MMP-3 and anti-
HAS-2 antibodies after 6 days of daily topical application of the
vehicle gel, the fixed-combination gel, and the mono-components in
the corresponding vehicle gel. Three replicates were used for each
treatment. Signals were visualized with a fluorescence microscope.
Scale bar is 50 lm. b Quantifications of immunostainings performed
with ImageJ software. Values in the histograms are normalized
relative to vehicle controls
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In contrast, mean epidermal thickness was significantly
reduced by treatment with betamethasone but modestly
increased by calcipotriol (however, the effect by calcipotriol
was not significantly different from the vehicle group). Thus,
the decreased HA synthesis in keratinocytes induced by
betamethasone in vitro and ex vivo seems to correlate with
reduced epidermal thickness in minipigs in vivo. Similarly,
the increased HA synthesis induced by calcipotriol in vitro
and ex vivo seems to correlate with a modest increase in
epidermal thickness in vivo. Finally, in accordance with the
in vitro and ex vivo data on HA modulation, treatment with
the calcipotriol/betamethasone gel maintained epidermal
thickness comparable to the controls in minipigs, showing
that calcipotriol was able to prevent betamethasone-induced
epidermal thinning.
Discussion
The effects of glucocorticoids on extracellular matrix
components have been studied in monolayer cultures of
human dermal fibroblasts by several groups, however,
with rather divergent results [1, 28, 33]. In one study,
treatment with glucocorticoids for one to five days showed
no effect on COL1A1 and COL3A1 mRNA expression
while HAS2 mRNA expression and HA production were
significantly suppressed [1]. In another study, treatment
with glucocorticoids for 24 h did not affect COL1A1 and
COL3A1 mRNA expression in human or rat dermal
fibroblasts. In contrast, the mRNA expression for these
genes was strongly suppressed in 3T3 mouse embryonic
fibroblasts [28], suggesting dependent differences. How-
ever, Weindl et al. [33] demonstrated a marked down-
regulation of COL1A1, less inhibition of COL3A1 but no
effects on COL1A2, COL4A1 and MMP1 mRNA expres-
sion in human dermal fibroblasts. Possible explanations
for these apparently contradicting findings may relate to
the assay conditions and more specifically the addition of
serum to the assay media. In the two first studies [1, 28],
glucocorticoids were tested in human dermal fibroblast
cultures supplemented with serum (at which concentration
and whether charcoal-treated serum was used is not
specified in the publications). The third study was appar-
ently conducted without supplementation of the culture
medium with serum or growth factors during the experi-
ment [33]. The lack of serum may significantly impair the
physiological responses of fibroblasts with noticeable
changes in cell proliferation and morphology. Such vari-
ations in culture conditions may well explain the differing
results. Using our growth conditions (1.9 % charcoal-
treated serum plus supplementation as described), we find
that treatment with glucocorticoids result in detectable but
modest effects on COL1A1 mRNA expression and CICP
secretion whereas stronger suppression is seen on HAS2
mRNA expression and secretion of HA, MMP-1 and
MMP-3.
As monolayer cultures lack organotypic features,
mechanisms of glucocorticoid-induced skin atrophy have
been explored in reconstructed human full-thickness skin
models. In studies using the Phenion-FT skin model
(Henkel KGaA), a marked decrease in collagen I synthesis
and reduction in epidermal layers was observed by addition
of glucocorticoids to the culture medium as well as by
topical application for 11–14 days [28, 35]. However, the
fact that Zoller et al. [35] reported up to 20–30 % reduction
in epidermal layers of untreated or vehicle controls during
this extended treatment period suggests a possible con-
founding effect. In contrast to these findings, another study
using the EpiDerm FT skin model (MatTek Corp.) reported
no effect of glucocorticoids on mRNA expression of
COL1A1 and MMP1 and on epidermal thickness after
topical application for 7 days [33]. The seemingly contra-
dictive results from these studies may be caused by the
different treatment schedules but also by the specific fea-
tures of these skin models. In our experience, the Phenion-





















Fig. 5 Calcipotriol prevents betamethasone-induced epidermal thin-
ning in minipigs. Go¨ttingen minipigs were dosed topically with the
vehicle gel, the calcipotriol/betamethasone gel, or the mono-compo-
nents in the corresponding vehicle gel for a total of 4 weeks.
Epidermal thickness was analyzed on Masson’s trichrome-stained
sections (mean ± SD). The vehicle group was used as reference for
testing significance of treatment by a mixed effects model with
thickness as a fixed effect and animal and treatment field as random
effects (R version 2.15.2). *P \ 0.05
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FT model has higher mechanical stability and contains
more epidermal layers than the EpiDerm FT skin model.
Some drawbacks of reconstructed skin models relate to
their highly permeable skin barrier compared to normal
skin and the morphological changes and decrease in epi-
dermal layers typically seen during prolonged culture and
upon repeated topical application of vehicles. Due to these
confounders, the use of human skin explants may offer a
more relevant option in terms of translation to human skin
in vivo. Here, we use the NativeSkin model containing
full-thickness human skin embedded in a proprietary
matrix. Compared to human skin explants using standard
culture conditions, the NativeSkin model provides the
opportunity to perform repeated daily topical application
up to a week without affecting skin morphology and epi-
dermal layers of the explant (Supplementary Fig. 5).
In the present study we have used several different
readouts to assess the impact of betamethasone on collagen
I synthesis. We show that betamethasone treatment for 24
and 48 h resulted in a minor inhibition of COL1A1 mRNA
but a significant decrease of CICP secretion in primary
human dermal fibroblasts in vitro. Furthermore, immuno-
fluorescence analysis shows that betamethasone treatment
reduced pro-collagen I in the NativeSkin explant model.
In addition to the effect on collagen I synthesis, beta-
methasone treatment significantly reduced the secretion of
MMP-1 in both fibroblasts and keratinocytes in vitro.
These findings are in line with published studies and sup-
port the concept that glucocorticoids restrict remodeling
and adaptation of the skin by diminishing collagen syn-
thesis and collagenase (MMP-1) production [2, 4, 5, 20, 24,
28]. Likewise, MMP-3 secretion was significantly
decreased by betamethasone treatment in both fibroblasts
and keratinocytes in vitro as well as in the human skin
explant model. In contrast, MMP-1 expression in the
human skin explant model was unaffected by betametha-
sone treatment at the investigated time point.
Previous studies in hairless mice have suggested that
vitamin D receptor agonists may counteract glucocorticoid-
induced skin atrophy and induce collagen synthesis [10,
11]. However, a potential confounder of these studies is the
use of the highly potent vitamin D analog (KH1060) which
is known to induce skin irritation and skin thickening in
mice [11]. In the present study we show that calcipotriol
was able to prevent betamethasone-induced suppression of
collagen I synthesis in human dermal fibroblasts in vitro as
well as in the human skin explant model treated with the
calcipotriol/betamethasone gel. The differential effects of
betamethasone and calcipotriol on collagen I synthesis
could maybe be explained by differential effects on TGF-
beta which positively regulates the expression of the
COL1A1 gene [32]. Glucocorticoids have been found to
decrease TGF-beta expression whereas vitamin D has been
shown to increase TGF-beta expression in both dermal
fibroblasts and keratinocytes [12, 21, 25].
Vitamin D has previously been shown to increase the
expression of MMP-1 and MMP-3 in human synovial
fibroblasts [30]. To our knowledge, there are no published
studies addressing the effect of vitamin D on MMP
expression in keratinocytes. Our in vitro results demon-
strate that calcipotriol enhanced levels of MMP-3 in dermal
fibroblasts and in keratinocytes whereas calcipotriol only
significantly augmented MMP-1 levels in keratinocytes but
not in dermal fibroblasts. In the human skin explant model,
calcipotriol maintained levels of MMP-1 and MMP-3 even
in the presence of betamethasone upon treatment with the
calcipotriol/betamethasone gel.
Glucocorticoids have been shown to decrease HAS2
mRNA expression as well as production of HA in fibro-
blasts and keratinocytes in vitro and to reduce dermal HA
levels in human skin in vivo [8]. Our results confirm that
betamethasone treatment impairs both HAS2 expression
and HA secretion in vitro. Furthermore, we show that the
decreased HA synthesis induced by betamethasone in
keratinocytes in vitro and in the human skin explant model
translates to reduced epidermal thickness in minipigs.
So far, no published studies have investigated VDR
agonist-induced effects on HA in the skin. Our in vitro
results indicate that calcipotriol has differential effects on
HA in fibroblasts and keratinocytes. Calcipotriol increased
HA secretion and counteracted the betamethasone-induced
decrease in keratinocytes. In contrast, HAS2 expression and
HA secretion in fibroblasts remained unaffected by calci-
potriol. TGF-beta has also been reported to induce HAS2
expression in human dermal fibroblasts [6, 22]. The
reported glucocorticoid-mediated decrease in TGF-beta
expression correlates with the betamethasone-induced
downregulation of HAS2 in fibroblasts whereas no corre-
lation is observed between the reported effect of calcipot-
riol on TGF-beta expression and lack of effect on HA
secretion in fibroblasts.
Similarly, in the skin explant model calcipotriol restored
betamethasone-decreased HAS-2 expression in the epi-
dermis and furthermore prevented betamethasone-induced
epidermal thinning in minipigs upon treatment with the
calcipotriol/betamethasone gel. Interestingly, another study
have reported that intermediate-size HA fragments induced
keratinocyte proliferation in vitro as well as epidermal
hyperplasia in vivo and reversed glucocorticoid-induced
epidermal thinning in humans [16].
A previous clinical study in healthy human volunteers
has investigated the effect of the calcipotriol/betametha-
sone combination on skin thickness as assessed by
sonography [31]. In this study, the combination treatment
reduced total skin thickness by approximately 15 % after
4 weeks of treatment comparable to the effect of
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betamethasone dipropionate alone. The treatment effect
was confined to the dermis as no treatment effect was
seen on epidermal thickness. The reduction in skin
thickness observed in this clinical study can maybe be
explained by a rapid loss of water binding capacity in the
dermis due to a decrease of HA. This is further supported
by the fast recovery of skin thickness observed upon
termination of treatment. The reported reduction in der-
mal thickness by calcipotriol/betamethasone is in contrast
to our finding that calcipotriol counteracts betamethasone-
induced decrease in collagen I synthesis. However, it is
likely that the 4 week duration of the clinical study was
too short as to reveal a counteracting effect of calcipotriol
on dermal thickness via a stimulation of collagen
production.
In summary, our results overall confirm the previously
reported atrophogenic effect of glucocorticoids via
decrease of key ECM components in the skin. Of notice,
we show for the first time in primary human skin cultures
that calcipotriol reduces early signs of betamethasone-
induced skin atrophy by modulation of ECM components.
These results provide a probable mechanism behind a
favorable safety profile of the two-compound fixed-com-
bination gel for topical treatment of psoriasis.
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